A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide

被引：0

作者：

Rizzello, Ilaria ^{[1
]}

Sacchetti, Ilaria ^{[1
]}

Barbato, Simona ^{[1
]}

Solli, Vincenza ^{[1
]}

Stefanoni, Paola ^{[2
]}

Cani, Lorenzo ^{[3
]}

Pavan, Laura ^{[4
]}

Quaresima, Micol ^{[5
]}

Belotti, Angelo ^{[6
]}

Sgherza, Nicola ^{[7
]}

Gentile, Massimo ^{[8
]}

Barila, Gregorio ^{[9
]}

Patriarca, Francesca ^{[10
]}

Celli, Melania ^{[11
]}

Vincelli, Iolanda Donatella ^{[12
]}

Mancuso, Katia ^{[1
]}

Sartor, Chiara ^{[1
]}

Pantani, Lucia ^{[1
]}

Tacchetti, Paola ^{[1
]}

Talarico, Marco ^{[1
]}

Puppi, Michele ^{[1
]}

Bigi, Flavia ^{[1
]}

Cavo, Michele ^{[1
]}

Zamagni, Elena ^{[1
]}

机构：

[1] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[2] ASST Papa Giovanni XXIII, Dept Oncol & Hematol, Bergamo, Italy

[3] AOU Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[4] AOU Padova, Ematol, Padua, Italy

[5] AUSL Reggio Emilia, Ematol, Reggio Emilia, Italy

[6] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[7] AOUC Policlin, Hematol, Bari, Italy

[8] AO Cosenza, Dept Oncohematol, Hematol Unit, Cosenza, Italy

[9] Osped San Bortolo, Ematol, Vicenza, Italy

[10] Azienda Sanit Univ Friuli Cent, Clin Ematol, Cosenza, Italy

[11] Osped Infermi Rimini, UO Ematol, Rimini, Italy

[12] GOM Bianchi Melacrino Morelli, UOC Ematol, Reggio Di Calabria, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-416

引用

页码：S275 / S275

页数：1

共 50 条

[21] Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
Dimopoulos, Meletios A.
Kastritis, Efstathios
Christoulas, Dimitrios
Migkou, Magdalini
Gavriatopoulou, Maria
Gkotzamanidou, Maria
Iakovaki, Marina
Roussou, Maria
Efstathiou, Eleni
Terpos, Evangelos
BLOOD, 2009, 114 (22) : 395 - 396
[22] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Paludo, Jonas
Mikhael, Joseph R.
LaPlant, Betsy R.
Halvorson, Alese E.
Kumar, Shaji
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis K.
Dispenzieri, Angela
Lust, John A.
Kapoor, Prashant
Leung, Nelson
Russell, Stephen J.
Dingli, David
Go, Ronald S.
Lin, Yi
Gonsalves, Wilson I.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
Ailawadhi, Sikander
Stewart, A. Keith
Reeder, Craig B.
Richardson, Paul G.
Rajkumar, S. Vincent
Lacy, Martha Q.
BLOOD, 2017, 130 (10) : 1198 - 1204
[23] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
Yasuo Mori
Ilseung Choi
Goichi Yoshimoto
Tsuyoshi Muta
Satoshi Yamasaki
Kazuki Tanimoto
Tomohiko Kamimura
Hiromi Iwasaki
Ryosuke Ogawa
Koichi Akashi
Toshihiro Miyamoto
International Journal of Hematology, 2020, 111 : 673 - 680
[24] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
Mori, Yasuo
Choi, Ilseung
Yoshimoto, Goichi
Muta, Tsuyoshi
Yamasaki, Satoshi
Tanimoto, Kazuki
Kamimura, Tomohiko
Iwasaki, Hiromi
Ogawa, Ryosuke
Akashi, Koichi
Miyamoto, Toshihiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
[25] Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
Bernard Regidor
Marissa-Skye Goldwater
Jessica Wang
Sean Bujarski
Regina Swift
Benjamin Eades
Marsiye Emamy-Sadr
Shahrooz Eshagian
Gary Schwartz
Tanya M. Spektor
James R. Berenson
Annals of Hematology, 2021, 100 : 2061 - 2070
[26] Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Alsina, M.
Ghobrial, I.
Knight, R.
Esseltine, D.
Richardson, P.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[27] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
Anderson, K. C.
Weller, E.
Lonial, S.
Jakubowiak, A. J.
Jagannath, S.
Raje, N. S.
Avigan, D.
Knight, R. D.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[28] Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
Hansen, Doris K.
Gautam, Santosh
Lafeuille, Marie-Helene
Rossi, Carmine
Moore, Bronwyn
Tardif-Samson, Anabelle
Thompson-Leduc, Philippe
Fu, Alex Z.
Cortoos, Annelore
Kaila, Shuchita
Fonseca, Rafael
BLOOD, 2023, 142
[29] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
Palumbo, A.
Chanan-Khan, A.
Weisel, K.
Nooka, A. K.
Masszi, T.
Beksac, M.
Spicka, I.
Hungria, V.
Munder, M.
Mateos, M. V.
Mark, T.
Qi, M.
Schecter, J.
Amin, H.
Qin, X.
Deraedt, W.
Ahmadi, T.
Spencer, A.
Sonneveld, P.
HAEMATOLOGICA, 2016, 101 : 340 - 341
[30] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
Moustafa, Muhamad Alhaj
Parrondo, Ricardo
Abdulazeez, Mays F.
Roy, Vivek
Sher, Taimur
Alegria, Victoria R.
Warsame, Rahma M.
Larsen, Jeremy
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Kapoor, Prashant
Fonseca, Rafael
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Reeder, Craig B.
Agrawal, Arshi
Chanan-Khan, Asher A.
Ailawadhi, Sikander
BLOOD, 2020, 136

← 1 2 3 4 5 →